PALLD

Across TCGA pan-cancer cohorts, PALLD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PALLD data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PALLD mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PALLD expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

GBM, CCRCC, and LSCC are the cancer types where PALLD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.249	0.506	.002	21	view →
CCRCC	OS	Tertile	IV	0.198	0.830	.024	18	view →
LSCC	DFS	Quartile	II,III,IV	0.683	0.954	.006	16	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	12	view →
LUAD	OS	Quartile	All	1.000	0.946	.025	3	view →
HNSC	DFS	Median	II,III,IV	0.976	0.916	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PALLD–GBM (OS)

Open the GBM breakdown →